Cannabis for dyskinesia in Parkinson disease

@article{Carroll2004CannabisFD,
  title={Cannabis for dyskinesia in Parkinson disease},
  author={Camille B Carroll and Peter G Bain and Lara Teare and X Liu and Cuhk Joint and C. Wroath and Simon Parkin and P Fox and David Wright and Jeremy Charles Hobart and John P. Zajicek},
  journal={Neurology},
  year={2004},
  volume={63},
  pages={1245 - 1250}
}
Background: The long-term treatment of Parkinson disease (PD) may be complicated by the development of levodopa-induced dyskinesia. Clinical and animal model data support the view that modulation of cannabinoid function may exert an antidyskinetic effect. The authors conducted a randomized, double-blind, placebo-controlled crossover trial to examine the hypothesis that cannabis may have a beneficial effect on dyskinesia in PD. Methods: A 4-week dose escalation study was performed to assess the… 

Figures and Tables from this paper

Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study
TLDR
The study illustrated the complexities of finding the basis of patients’ observation of improvement and oral Cannador does not have a therapeutic role in the treatment of dyskinesia in this study group and future studies of systemic effects should use routes of administration that do not make a first pass through the liver.
Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
TLDR
CBD was well tolerated, and all three studies reported significant therapeutic effects in non-motor symptoms of PD, however, sample sizes were small and CBD treatment was short, so large-scale RCTs are needed to try to replicate these results and to assess the long-term safety of CBD.
Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)
TLDR
The reduction of harm through an ineffective treatment, the possibility of individualized dosing, the reduction of sample size, and the possible evaluation of the influence of the placebo effect on efficacy outcomes justify this design for a single-centered placebo-controlled investigator-initiated trial of nabilone.
Effects of Cannabis in Parkinson’s Disease: A Systematic Review and Meta-Analysis
TLDR
No compelling evidence was found to recommend the use of cannabis in PD patients, but a potential benefit was identified with respect to alleviation of PD related tremor, anxiety, pain, improvement of sleep quality and quality of life.
Dyskinesia in Parkinson's Disease Therapy
TLDR
This Special Issue discusses recent breakthroughs in this direction and provides an update of the clinical features and management of L-DOPA-induced dyskinesia, and describes the management of this condition, based on the use of various types of dopaminergic agonists.
Evidence for the use of cannabinoids in Parkinson’s disease
TLDR
An overview of the current literature in the field of cannabinoids and their effect on Parkinson’s disease is provided and a pragmatic approach for the clinical use of cannabinoids in PD is discussed.
Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics
TLDR
Clinical research is reviewed using various formulations of cannabis (botanical products, oral preparations containing ∆9-tetrahydrocannabinol and/or cannabidiol) and currently available preparations in the USA (nabilone and dronabinol), expanded from a recent systematic review to include case reports and case series and results of anonymous surveys of patients using cannabis outside of medical settings.
Therapy for dyskinesias in Parkinson's disease patients
TLDR
Deep brain stimulation in the subthalamic nucleus has proved efficacious in reducing LID, largely because it allows a reduction in dopaminergic daily doses.
...
...

References

SHOWING 1-10 OF 34 REFERENCES
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
TLDR
The beneficial effects of amantadine on motor response complications are maintained for at least 1 year after treatment initiation, and motor complications occurring with the patients' regular oral levodopa regimen also remained improved according to the Unified Parkinson's Disease Rating Scale (UPDRS-IV).
Amantadine for dyskinesia in patients affected by severe Parkinson's disease
TLDR
Patients affected by severe Parkinson's disease with peakdose and/or diphasic dyskinesias or painful Dyskinesia were treated with amantadine as adjunctive therapy to current levodopa, carbidopa and dopaminoagonist, and UPDRS, DRS and IGA scale were used to evaluate the severity of PD symptoms during follow-up.
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
TLDR
It is demonstrated that the cannabinoid receptor agonist nabilone significantly reduces levodopa-induced dyskinesia in PD.
Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease
TLDR
It is indicated that dronabinol is a promising novel therapeutic agent which may be useful not only for treatment of anorexia but also to improve disturbed behavior in patients with Alzheimer's disease.
Unawareness of dyskinesias in Parkinson's and Huntington's diseases
TLDR
In PD the unawareness seems to be inversely related with severity of dyskinesias, while in HD it is directly related to disease duration and severity.
Open label evaluation of cannabidiol in dystonic movement disorders.
TLDR
Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study and appears to have antidystonic and Parkinsonism-aggravating effects in humans.
Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
TLDR
Testing the hypothesis that the cannabinoid receptor agonist nabilone would alleviate levodopa‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine hydrochloride ‐lesioned marmoset model of Parkinson's disease found it to be useful in the treatment of motor complications in Parkinson’s disease.
Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
TLDR
A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonIA following treatment with nabil one.
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high‐dose levodopa in the reserpine‐treated rat model of Parkinson's disease
TLDR
The data suggest that both CB1 cannabinoid receptor antagonists and agonists can modulate the behavioural effects of L‐dopa and may be useful for the treatment of the dyskinesia associated with long‐term L‐ dopa treatment of Parkinson's disease.
...
...